Skip to main content

Advertisement

Log in

Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease

  • Brief Report
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

This study aimed to assess the effect of mofetil mycophenolate (MMF), an inhibitor of lymphocyte proliferation, on lung function and skin in patients with systemic sclerosis (SSc)-associated interstitial lung disease (SSc-ILD). In this retrospective study, we reviewed the medical files of 10 patients with SSc-ILD (eight females, 10 patients with diffuse SSc; mean age, 59.7 ± 12.7 years; disease duration, 7.7 ± 4.7 years). Patients were treated with MMF (2 g/day) for 12 months. Lung function tests and the modified Rodnan total skin score (mRTSS) were assessed at baseline and at 12 months. Results were analyzed by paired Student’s t test. There was a significant increase in forced vital capacity and a nonsignificant increase in carbon monoxide diffusing capacity at 12 months in patients on MMF (p = 0.04 and 0.66, respectively). There was no effect on mRTSS. MMF stabilizes lung function of SSc-ILD after 12 months of treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Steen VD, Medsger TA (2007) Changes in causes of death in systemic sclerosis, 1972–2002. Ann Rheum Dis 66:940–944

    Article  PubMed  Google Scholar 

  2. Vanthuyne M, Blockmans D, Westhovens R, Roufosse F, Cogan E, Coche E et al (2007) A pilot study of mycophenolate mofetil combined to intravenous methylprednisolone pulses and oral low-dose glucocorticoids in severe early systemic sclerosis. Clin Exp Rheumatol 25:169–171

    Google Scholar 

  3. Gerbino AJ, Goss CH, Molitor JA (2008) Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. Chest 133:455–460

    Article  CAS  PubMed  Google Scholar 

  4. Liossis SNC, Bounas A, Andonopoulos AP (2006) Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. Rheumatology 45:1005–1008

    Article  CAS  PubMed  Google Scholar 

  5. Zamora AC, Wolters PJ, Collard HR, Connolly MK, Elicker BM, Webb WR et al (2008) Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Respir Med 102:150–155

    Article  PubMed  Google Scholar 

  6. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE et al (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354:2655–2666

    Article  CAS  PubMed  Google Scholar 

  7. Tashkin DT, Elashoff R, Clements PJ, Roth MD, Furst DE, Silver RM et al (2007) Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 176:1026–1034

    Article  CAS  PubMed  Google Scholar 

  8. Daoussis D, Liossis SN, Tsamandas AC, Kalogeropoulou C, Kazantzi A, Sirinian C et al (2009) Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology 49:271–280. doi:10.1093/rheumatology/kep093

    Article  PubMed  Google Scholar 

  9. Lafyatis R, Kissin E, York M, Farina G, Viger K, Fritzler MJ et al (2009) B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 60:578–583

    Article  PubMed  Google Scholar 

  10. Sfikakis PP, Gorgoulis VG, Katsiari CG, Evangelou K, Kostopoulos C, Black CM (2008) Imatinib for the treatment of refractory, diffuse systemic sclerosis. Rheumatology 47:735–737

    Article  CAS  PubMed  Google Scholar 

  11. Sabnani I, Zucker MJ, Rosenstein ED, Baran DA, Arroyo LH, Tsang P et al (2009) A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide. Rheumatology 48:49–52

    Article  CAS  PubMed  Google Scholar 

  12. Greenwald GI, Tashkin DP, Gong H, Simmons M, Duann S, Furst DE et al (1987) Longitudinal changes in lung function and respiratory symptoms in progressive systemic sclerosis: prospective study. Am J Med 83:83–92

    Article  CAS  PubMed  Google Scholar 

  13. Steen VD, Conte C, Owens GR, Medsger TA (1994) Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 37:1283–1289

    Article  CAS  PubMed  Google Scholar 

  14. Steen VD, Owens GR, Redmond C, Rodnan GP, Medsger TA (1985) The effect of d-penicillamine on pulmonary findings in systemic sclerosis. Arthritis Rheum 20:882–888

    Article  Google Scholar 

Download references

Disclosures

None

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Lazaros I. Sakkas.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Koutroumpas, A., Ziogas, A., Alexiou, I. et al. Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease. Clin Rheumatol 29, 1167–1168 (2010). https://doi.org/10.1007/s10067-010-1498-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-010-1498-z

Keywords

Navigation